Global DDimer Test Market By Overview
D-Dimer Test Market was valued at USD 1.4 Billion in 2024 and is projected to grow at a CAGR of 4.5 % to reach USD 2.2 Billion by 2034.
D Dimer Test is a kind of blood test detecting the presence of D-dimer in the blood. D-dimer is a protein fragment of fibrin formed after Fibrinolysis degradation of blood clot. D-dimers test helps to diagnose the conditions with abnormal blood clots formation and breakdown, intravascular fibrinolysis, and coagulation. Genetic disorders that increase the risk of blood clot formation are rare but can have serious health implications. High D-dimer levels indicates clinical suspicion of a blood clot and needs ultrasound, CT angiography, scans could be performed to confirm the presence of clot and location of clot. D-Dimer test is not specific to any disease and thus is performed in conjunction with other evaluations and diagnostic tests. 0.5 is measured as normal range for D-dimer and greater than 0.5 is measured to be positive. D-dimer decreases under abnormal medical case which is measured by specific antibodies.
Global DDimer Test Market By Drivers & Restraints
DRIVERS:
Advantages of D-Dimer Testing
D-dimer testing has replaced traditional testing services, allowing for faster test results, quicker diagnosis, shorter patient wait times, and better patient outcomes overall. D-Dimer testing to be more widely used by customers offering compelling advantages. Additionally, the growing prevalence of lung and cardiovascular illnesses might, in extreme circumstances, lead to potentially fatal blood clot problems, which propels D-Dimer Test Market.
Growing prevalence of Blood clot related genetic disorders
Rise in incidence of Thrombus embolism along with various cardiovascular and pulmonary diseases that could be life threating due to clot formation increases the demand for D-Dimer Test Market. D-dimer functions as valuable marker in various clinical conditions such as HIV, atrial fibrillation, coronary artery disease. New technological advancement such as development of aptamers, reducing use of antibodies for D-dimer testing being cost-effective, long-lasting boosts D-Dimer Test Market broadening the application scope of these tests.
RESTRAINS:
Lack of trained healthcare professionals and reimbursement scenario
Lack of skilled professionals and trained professionals unable to perform the test properly and lack of knowledge leads to false results and restrains the D-Dimer test Market. High cost and poor reimbursement policies restrains people to take such tests for proper diagnosis increasing the prevalence of disease and deaths.
Global DDimer Test Market By Segmentations & Regional Insights
D-Dimer Test Market is segmented based on Testing Type, Diseases, End-User and Region.
By Testing Methods |
By Diseases |
By End-User |
By Region |
|
|
|
|
Testing Methods Insights
On the basis Testing Methods, the target market is segmented into Coagulation Analyzers and Clinical Chemistry Analyzers. Coagulation analyzers analysis blood clots typically using ELISA method holding the largest share in D-Dimer Test Market. They are highly sensitive, detects even low levels of D-Dimer in the sample. Increase in availability of these tests boosts the segment in D-Dimer test market.
Diseases Insights
On the basis of Diseases, the target market is segmented into Deep Vein Thrombosis, Pulmonary Embolism and Disseminated Intravascular Coagulation. Pulmonary embolism is prevailing nowadays and thus holds a biggest share in boosting the D-Dimer Test Market. According to CDC 2022 update, 900,000 people are affected by pulmonary embolism in United States.
End-User Insights
On the basis of End User, the target market is segmented into Hospitals, Clinics, Research Institutes and Diagnostics Laboratories. The hospital segment captured the highest segment in D-Dimer testing Market. Several studies proved that hospitalized patients are more at risk of developing pulmonary embolism and is third most common cause of mortality in hospitalized patients. High incidence of pulmonary embolism in hospitals leads to large adoption of D-Dimer Test in Hospitals boosting the D-Dimer Test Market.
The diagnostic centers also support to the growth of targeted market offering lower costs as compared to hospitals. Decreased waiting time and patient satisfaction leading to great interest among the patients to undergo rapid tests at diagnostic centers.
- North America market is estimated to witness a significantly high revenue share over the forecast period due to rising prevalence of cardiovascular diseases, blood clot related genetic disorders among the huge population leads to higher demand for D-Dimer Test Market in the forecast period. Better healthcare infrastructure, healthcare professionals, key players in the market accounts for higher share of the region in forecast period.
- Asia Pacific market is estimated to witness a fastest revenue share over the forecast period due to advanced technological advancements in healthcare sectors, supportive guidelines by government and private organizations. Healthcare infrastructure, increasing awareness regarding genetic disorders and its effects lead to D-Dimer Test Market growth in the region.
Report Scope:
Attribute |
Details |
Base year for estimation |
2024 |
Forecast period |
2024 – 2034 |
Market representation |
Revenue in USD Billion & CAGR from 2024 to 2034 |
Market Segmentation |
By Testing methods, Disease, End user |
Regional scope |
North America ,Europe ,Asia Pacific ,Latin America, Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034.
Few Other Promising Reports:
Global DDimer Test Market By Competitive Landscape & Key Players
- Beckman Coulter, Inc.
- Bio/Data Corporation
- Becton Dickinson BV
- Sysmex Corporation
- Abbott Laboratories, Inc.
- Dickinson and Company
- Hoffman-La Roche Ltd.
- Helena Biosciences Ltd.
- Grifols S.A.
- Siemens Healthcare, Inc.
Global DDimer Test Market By Recent News
The New Launched Product News,
- In September 2023, Finding was published in Nature Medicine, suggesting links between brain fog in long COVID and “micro clots” in the blood. These clots often contain misfolded fibrinogen proteins that prevent the clots from breaking down, and this effect can clog blood vessels and block oxygen flow to the brain and other organs. Blood tests for both D-dimer and fibrinogen are already standard around the world, so researchers had plenty of available data to check whether the same phenomenon occurred in other groups of patients.
- In June 2022, LumiraDx Limited, a next-generation point of care Diagnostics Company, announced its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-Dimer test to now rule out venous thromboembolism (VTE) in symptomatic patients. With these two additions, the LumiraDx Platform can further support clinicians in quickly and accurately assessing patient symptoms for both VTE and heart failure at the point of care. The LumiraDx NT-proBNP test is a rapid microfluidic immunofluorescence assay for the quantitative measurement of NT-proBNP in human capillary, venous whole blood and plasma specimens.
FAQs
The D-dimer test market report segments the market on the basis of testing methods, diseases type, end use, and region.
The potential for false-positive results, leading to unnecessary testing and healthcare costs, and challenges in standardizing D-dimer assays across different laboratories, affecting result consistency.
Rising incidence of thrombotic disorders and the increasing use of D-dimer testing in the diagnosis and management of conditions such as deep vein thrombosis and pulmonary embolism.
By region, the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.
Beckman Coulter, Inc.,Bio/Data Corporation,Becton Dickinson BV ,Sysmex Corporation,Abbott ,aboratories, Inc.,Dickinson and Company,Hoffman-La Roche Ltd.,Helena Biosciences Ltd.,Grifols S.A.Siemens Healthcare, Inc.